S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
BLTE · Belite Bio, Inc American Depositary Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$154.30
-0.39
(-0.25%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$154.30
$152.47
$156.78
52-WEEK RANGE
$154.30
$86.57
$200.00
What's happening
- BLTE is down 0.25% today, trading at $154.30. — Live quote
- Volume today (4,302) is well below its 3-month average of 192,290. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.70 actual vs. $-0.80 estimated (+13.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
BLTE
-3.44%
vs S&P 500
-16.22%
1-YEAR RETURN
BLTE
+70.91%
vs S&P 500
+56.35%
6-MONTH RETURN
BLTE
-2.28%
3-MONTH RETURN
BLTE
-4.12%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.70
Est. $-0.80
BEAT +13.0%
2026-04-26 (Q1 2026)
$-0.68
Est. $-0.65
MISS -4.9%
2026-01-26 (Q4 2025)
$-0.70
Est. $-0.56
MISS -25.6%
2025-10-26 (Q3 2025)
$-0.65
Est. $-0.50
MISS -30.7%
Valuation Measures & Ratios
Enterprise Value4$5.58B
Forward P/E5—
PEG Ratio6-0.70
Price / Sales (TTM1)—
Price / Book77.28
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-26.87%
Return on Assets (ROA9)-26.26%
Avg Volume (3M)192,290
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,057,536
Change from Prior Settlement+0.67%
% of Float—
Days to Cover (Short Ratio)7.28
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +70.9%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-05; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BLTE
No accessible free API for these — links go to the source directly.
Financials
Financial statement data not available for this company — SEC EDGAR XBRL coverage only includes US GAAP 10-K/10-Q filers.
Institutional holders
SEC Form 13F filers holding BLTE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-17 to 2026-10-01
Recent transactions
- Insiders have net sold 200,728 shares over the last 182 days, across 0 purchases and 136 sales.
- Most recent: Scholl Hendrik Peter (Chief Medical Officer) — Open market sale of 200 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)200,728 sh(136 txns)
Net Shares-200,728
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 2026-10-01 | 200 |
| Lin Yu-Hsin | Chief Executive Officer | Open market sale | 2026-09-08 | 2,400 |
| Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 2026-09-08 | 2,200 |
| MATA NATHAN L. | Chief Scientific Officer | Open market sale | 2026-05-07 | 226 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 200 | $163.62 |
| 2026-10-01 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 24 | $164.64 |
| 2026-10-01 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 120 | $165.49 |
| 2026-10-01 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 50 | $166.44 |
| 2026-10-01 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 78 | $167.59 |
| 2026-10-01 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 12 | $168.21 |
| 2026-10-01 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 14 | $169.36 |
| 2026-10-01 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 2 | $170.02 |
| 2026-09-08 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 2,400 | $194.33 |
| 2026-09-08 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 6,090 | $195.62 |
| 2026-09-08 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 6,058 | $196.54 |
| 2026-09-08 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 8,752 | $197.36 |
| 2026-09-08 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 2,700 | $198.09 |
| 2026-09-08 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 2,200 | $194.28 |
| 2026-09-08 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 4,120 | $195.60 |
| 2026-09-08 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 4,475 | $196.47 |
| 2026-09-08 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 4,605 | $197.23 |
| 2026-09-08 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 2,562 | $198.05 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 2,635 | $180.29 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 2,587 | $181.24 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 3,413 | $182.50 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 4,955 | $183.30 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 6,252 | $184.52 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 4,593 | $185.34 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 7,800 | $186.32 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 6,200 | $187.25 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 3,045 | $188.26 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 8,955 | $189.34 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 600 | $190.39 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 11,080 | $191.15 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 4,209 | $192.54 |
| 2026-09-04 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 8,111 | $193.13 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 1,633 | $180.16 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 2,000 | $181.05 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 2,000 | $182.49 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 3,759 | $183.27 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 3,569 | $184.57 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 3,872 | $185.28 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 4,600 | $186.34 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 3,900 | $187.16 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 1,900 | $188.59 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 6,200 | $189.22 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 1,800 | $190.63 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 6,200 | $191.09 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 3,398 | $192.40 |
| 2026-09-04 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 4,602 | $193.12 |
| 2026-08-12 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 144 | $180.00 |
| 2026-08-12 | Chuang Hao-Yuan | Chief Financial Officer | Open market sale | 223 | $180.57 |
| 2026-08-12 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 142 | $180.00 |
| 2026-08-12 | Lin Yu-Hsin | Chief Executive Officer | Open market sale | 223 | $180.57 |
| 2026-06-18 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 96 | $143.90 |
| 2026-06-18 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 3,748 | $144.66 |
| 2026-06-18 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 4,861 | $145.43 |
| 2026-06-18 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 1,199 | $146.24 |
| 2026-06-18 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 96 | $147.11 |
| 2026-06-16 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 2,054 | $137.61 |
| 2026-06-16 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 784 | $138.18 |
| 2026-06-16 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 3,140 | $139.57 |
| 2026-06-16 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 540 | $140.58 |
| 2026-06-16 | Scholl Hendrik Peter | Chief Medical Officer | Open market sale | 100 | $141.83 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:05 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-05-08 | 4 | 2026-05-07 | View on SEC.gov → |
| 2026-05-07 | 4 | 2026-05-06 | View on SEC.gov → |
| 2026-05-06 | 4 | 2026-05-05 | View on SEC.gov → |
| 2026-05-05 | 4 | 2026-05-04 | View on SEC.gov → |
| 2026-05-04 | 4 | 2026-05-01 | View on SEC.gov → |
Recent news
Headlines about BLTE (Belite Bio, Inc American Depositary Shares). Links open the publisher — we don’t host full articles.
-
Why (BLTE) Price Action Is Critical for Tactical Trading
Stock Traders Daily · 2026-10-21 -
Belite Bio to uplist to Nasdaq Global Select Market
Seeking Alpha · 2026-10-19 -
Trading will start October 19 on a new Nasdaq tier for Belite Bio (NASDAQ: BLTE).
Stock Titan · 2026-10-19 -
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Yahoo · 2026-10-19 -
BLTE 6-K & SEC Filings
Yahoo Finance · 2026-10-19 -
Belite Bio Wins Nasdaq Global Select Listing, Trading Starts Oct. 19
Benzinga · 2026-10-19 -
Belite Bio Stock In Focus After Stargardt Drug Filings In Three Markets
Yahoo · 2026-10-17 -
Belite Bio (BLTE) Could Be 36% Undervalued On Tinlarebant Filing Progress
Simply Wall Street · 2026-10-16
No headlines in this category right now — try “All”.